GlassScriptPhysician profile
Cristina E Savu
NPI 1437448867
$3,441.06
in general payments reported to CMS, 2019-2025
24 companies · $578 in 2025
The $578 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $308 · 2020: $401 · 2021: $628 · 2022: $436 · 2023: $475 · 2024: $616 · 2025: $578.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,669.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,668.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $915.15 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $550.47 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Currax Pharmaceuticals LLC | $254.82 | 2021-2025 | Contrave, Onzetra Xsail, Nexlizet |
| Boehringer Ingelheim Pharmaceuticals, INC. | $197.98 | 2019-2025 | Jardiance, Synjardy, Trijardy Xr |
| Astrazeneca Pharmaceuticals LP | $197.05 | 2019-2024 | Breztri |
| Exact Sciences Corporation | $149.15 | 2023-2024 | Cologuard Collection Kit |
| Argon Medical Devices, INC. | $147.16 | 2025 | Clot Management |
| Amgen INC. | $144.80 | 2019-2025 | Repatha, Otezla, Otezla |
| Merck Sharp & Dohme LLC | $129.75 | 2019-2021 | |
| Astellas Pharma US INC | $118.90 | 2024-2025 | Veozah |
| Pfizer INC. | $101.80 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $96.44 | 2023 | |
| Janssen Pharmaceuticals, INC | $87.32 | 2021-2022 | |
| Abbvie INC. | $64.73 | 2023-2024 | Dalvance |
| Glaxosmithkline, LLC. | $53.98 | 2020-2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $46.32 | 2019-2021 | |
| Philips North America LLC | $42.88 | 2025 | Ambulatory Monitoring & Diagnostics Undivided |
| Hologic Sales and Service, LLC | $27.88 | 2024 | Aptima |
| Esperion Therapeutics, INC. | $27.67 | 2020 | |
| Abbott Laboratories | $22.91 | 2023 | Proclaim |
| Corcept Therapeutics | $22.16 | 2023 | Korlym |
| Kowa Pharmaceuticals America, INC. | $16.58 | 2021 | |
| Arbor Pharmaceuticals, INC. | $13.42 | 2019 | |
| Lucid Diagnostics INC. | $11.74 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cristina Savu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.